2015
Changes in melatonin synthesis parameters after carbon monoxide concentration increase in the cavernous sinus.
Romerowicz-Misielak M, Oren D, Sowa-Kucma M, Tabecka-Lonczynska A, Gilun P, Stefanczyk-Krzymowska S, Koziorowski M. Changes in melatonin synthesis parameters after carbon monoxide concentration increase in the cavernous sinus. Journal Of Physiology And Pharmacology 2015, 66: 505-14. PMID: 26348075.Peer-Reviewed Original ResearchConceptsOphthalmic venous bloodVenous bloodNocturnal melatonin riseMelatonin levelsMelatonin riseWinter seasonal affective disorderNocturnal melatonin peakSeasonal affective disorderHour infusionCavernous sinusVenous sinusesNon-physiological changesAutologous blood plasmaAffective disordersSynthesis of melatoninBright light effectsBloodAANAT protein levelsMelatonin peakProtein levelsAcute impactSinusTreatmentBlood plasmaParallel changes
2010
Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder
Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang S, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG. Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder. Depression And Anxiety 2010, 27: 417-425. PMID: 20455246, DOI: 10.1002/da.20695.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Anxiety AgentsAnxiety DisordersCitalopramDiagnostic and Statistical Manual of Mental DisordersDouble-Blind MethodFemaleHumansMaleMiddle AgedPharmacogeneticsPhenotypePolymorphism, Single NucleotidePsychometricsPyrazolesReceptors, Corticotropin-Releasing HormoneSeverity of Illness IndexTriazinesYoung AdultConceptsGeneralized anxiety disorderSingle nucleotide polymorphismsHamilton Anxiety Scale (HAMA) total scoreAnxiety disordersFactor receptor 1 antagonistActive comparator armCorticotropin-releasing factor receptorsActive comparator trialsPlacebo-controlled trialCorticotropin-releasing factor receptor 1 antagonistTreatment of GADPrimary outcome measurePlexin-A2Receptor 1 antagonistScale total scoreCRF-1 receptor antagonistClass of agentsComparator trialsComparator armPrimary outcomeActive comparatorEntire cohortRandomized subjectsReceptor antagonistMean change
2009
Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study
Young A, Oren D, Lowy A, McQuade R, Marcus R, Carson W, Spiller N, Torbeyns A, Sanchez R. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. The British Journal Of Psychiatry 2009, 194: 40-48. PMID: 19118324, DOI: 10.1192/bjp.bp.108.049965.Peer-Reviewed Original ResearchConceptsWeek 12Young Mania Rating Scale (YMRS) total scoreDouble-blind aripiprazoleHaloperidol-treated patientsTolerability of aripiprazoleExtrapyramidal adverse eventsScale total scoreMasked treatmentAdverse eventsClinical improvementAcute maniaAripiprazole monotherapyBipolar maniaMixed episodesEffective therapyEffect therapyAripiprazoleAdditional weeksHaloperidolWeek 3PlaceboPatientsTotal scoreTherapyMania
2008
A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia
Rappaport S, Marcus R, Manos G, McQuade R, Oren D. A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia. Journal Of The American Medical Directors Association 2008, 10: 21-27. PMID: 19111849, DOI: 10.1016/j.jamda.2008.06.006.Peer-Reviewed Original ResearchConceptsAgitation-Calmness Evaluation ScaleIM aripiprazoleIM placeboMixed dementiaIntramuscular aripiprazoleDoses 2 hoursIncidence of oversedationTreatment of agitationHealthcare facilitiesPreliminary efficacy analysisAdverse event reportingNegative Syndrome ScaleLong-term careAcute agitationEfficacy analysisTolerability studyPlaceboPEC scoresAripiprazoleGreater incidenceSyndrome ScaleGreater efficacyPatientsVital signsDementia
2007
Efficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations
DANIEL D, CURRIER G, ZIMBROFF D, ALLEN M, OREN D, MANOS G, MCQUADE R, PIKALOV A, CRANDALL D. Efficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations. Journal Of Psychiatric Practice 2007, 13: 170-177. PMID: 17522560, DOI: 10.1097/01.pra.0000271658.86845.81.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAdultAgedAntipsychotic AgentsAripiprazoleDouble-Blind MethodDyskinesia, Drug-InducedFemaleHaloperidolHumansInjections, IntramuscularMaleMiddle AgedPiperazinesPsychiatric Status Rating ScalesPsychomotor AgitationPsychotic DisordersQuinolonesSchizophreniaConceptsOral aripiprazoleOral formulationHaloperidol IMOral phaseIntramuscular formulationEfficacy measuresSchizoaffective disorderExtrapyramidal symptom-related adverse eventsPrimary efficacy measureStudy days 1Negative Syndrome ScalePlacebo IMAcute treatmentAdverse eventsGood tolerabilityClinical statusMean changePEC scoresPatientsDay 1HaloperidolAripiprazoleSyndrome ScaleInitial benefitComponent scoresIntramuscular Aripiprazole in the Control of Agitation
CURRIER G, CITROME L, ZIMBROFF D, OREN D, MANOS G, MCQUADE R, PIKALOV A, CRANDALL D. Intramuscular Aripiprazole in the Control of Agitation. Journal Of Psychiatric Practice 2007, 13: 159-169. PMID: 17522559, DOI: 10.1097/01.pra.0000271657.09717.e2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsAripiprazoleArousalBipolar DisorderDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleHaloperidolHumansHypnotics and SedativesInjections, IntramuscularLorazepamMaleMiddle AgedMulticenter Studies as TopicPiperazinesPsychiatric Status Rating ScalesPsychomotor AgitationQuinolonesRandomized Controlled Trials as TopicSchizophreniaSchizophrenic PsychologyTreatment OutcomeConceptsBipolar I disorderPEC scoresAripiprazole injectionI disordersBaseline agitationSecond injectionNegative Syndrome Scale Excited ComponentBaseline levelsSecondary analysisControl of agitationImportant clinical issueIntramuscular aripiprazoleAnalysis 3Clinical trialsAgitation symptomsMean changeNonspecific sedationPatientsBaseline scoresClinical issuesPlaceboAnalysis 2Analysis 1Study periodSchizophreniaManagement of Acute Agitation in Patients With Bipolar Disorder
Zimbroff D, Marcus R, Manos G, Stock E, McQuade R, Auby P, Oren D. Management of Acute Agitation in Patients With Bipolar Disorder. Journal Of Clinical Psychopharmacology 2007, 27: 171-176. PMID: 17414241, DOI: 10.1097/jcp.0b13e318033bd5e.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAnti-Anxiety AgentsAntipsychotic AgentsAripiprazoleBipolar DisorderDisorders of Excessive SomnolenceDizzinessDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleHeadacheHumansInjections, IntramuscularLorazepamMaleNauseaPatient DropoutsPiperazinesPsychomotor AgitationQuinolonesSleep Initiation and Maintenance DisordersTreatment OutcomeVomitingConceptsIM aripiprazoleIM placeboIM lorazepamAcute agitationActive treatmentEfficacy measuresFirst injectionBipolar disorderDouble-blind multicenter studyTreatment of agitationPrimary efficacy measureRisk-benefit profileComponent scoresAripiprazole dosesIntramuscular aripiprazoleOral aripiprazoleMixed episodesMulticenter studySafety profileEfficacy parametersLower incidenceMean changePlaceboAripiprazolePatientsEfficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
Tran-Johnson T, Sack D, Marcus R, Auby P, McQuade R, Oren D. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. The Journal Of Clinical Psychiatry 2007, 68: 111-9. PMID: 17284138, DOI: 10.4088/jcp.v68n0115.Peer-Reviewed Original ResearchConceptsPrimary efficacy measureIntramuscular aripiprazoleIM haloperidolIM aripiprazoleAcute agitationAdverse eventsEfficacy measuresTreatment-emergent adverse eventsCommon adverse eventsPlacebo-controlled trialPlacebo-controlled studyControl of agitationSchizo-affective disorderDSM-IV diagnosisNegative Syndrome ScaleHaloperidol groupIntramuscular haloperidolExtrapyramidal symptomsMore patientsInitial dosingSchizophreniform disorderMean changePlaceboSecondary measuresPEC scoresTreatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Robinson D, Gilmor M, Yang Y, Moonsammy G, Azzaro A, Oren D, Campbell B. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. Psychopharmacology Bulletin 2007, 40: 15-28. PMID: 18007565.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating ScaleMajor depressive disorderDepression Rating ScaleHAM-D28Rating ScaleDepressive disorderEfficacy trialsIndividual symptomsTreatment effectsPlacebo-controlled efficacy trialTransdermal systemSelegiline transdermal systemEnd of treatmentHamilton Rating ScaleBeneficial therapeutic effectsMajor monoamine neurotransmittersMonoamine oxidase inhibitorsRandom-effects modelCore depression symptomsGenital symptomsMADRS itemsDrug therapySignificant treatment effectTherapeutic effectSpecific symptoms
2006
Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study*
Andrezina R, Marcus R, Oren D, Manos G, Stock E, Carson W, McQuade R. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study*. Current Medical Research And Opinion 2006, 22: 2209-2219. PMID: 17076982, DOI: 10.1185/030079906x148445.Peer-Reviewed Original ResearchConceptsDouble-blind studyIM haloperidolIM placeboIntramuscular aripiprazoleIM aripiprazoleOral aripiprazoleOral therapyEfficacy measuresIM treatmentPEC scoresExtrapyramidal symptom-related adverse eventsSecondary efficacy measuresPrimary efficacy measureAripiprazole therapyAcute agitationAdverse eventsOral treatmentActive treatmentSafety profileIM injectionMean changeMean improvementPlaceboHaloperidolAripiprazoleIntramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol
Andrezina R, Josiassen R, Marcus R, Oren D, Manos G, Stock E, Carson W, Iwamoto T. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology 2006, 188: 281-292. PMID: 16953381, DOI: 10.1007/s00213-006-0541-x.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAdultAnti-Dyskinesia AgentsAntipsychotic AgentsAripiprazoleBasal Ganglia DiseasesBenzodiazepinesBlood GlucoseDouble-Blind MethodDrug Therapy, CombinationFemaleHaloperidolHumansInjections, IntramuscularMalePiperazinesPsychomotor AgitationPsychotic DisordersQuinolonesSchizophreniaTime FactorsTreatment OutcomeWithholding TreatmentConceptsIM aripiprazoleIM haloperidolAcute agitationIntramuscular aripiprazoleEfficacy measuresSchizoaffective disorderExtrapyramidal symptom-related adverse eventsPlacebo-controlled studySecondary efficacy measuresPercentage of patientsPlacebo-controlled comparisonPrimary efficacy measureIM placeboIntramuscular haloperidolAdverse eventsMethodsFour hundredThird injectionMean changePlaceboEffective treatmentHaloperidolPatientsAripiprazoleConclusionThese resultsMean numberTyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects
Azzaro A, VanDenBerg C, Blob L, Kemper E, Sharoky M, Oren D, Campbell B. Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects. The Journal Of Clinical Pharmacology 2006, 46: 933-944. PMID: 16855078, DOI: 10.1177/0091270006289852.Peer-Reviewed Original ResearchConceptsSelegiline transdermal systemTyramine sensitivity factorTransdermal systemOral tyramine pressor testDietary tyramine restrictionsTyramine pressor testTyramine pressor sensitivityDays of treatmentPressor dosesPressor sensitivityPressor testTranylcypromine treatmentHealthy malesHealthy subjectsHigh doseRatio of baselineExtended treatmentTreatmentCapsuleDaysCoadministrationSafety marginFactorsDoseDoses
2005
Circadian Phase Shifting, Alerting, and Antidepressant Effects of Bright Light Treatment
Postolache T, Oren D. Circadian Phase Shifting, Alerting, and Antidepressant Effects of Bright Light Treatment. Clinics In Sports Medicine 2005, 24: 381-413. PMID: 15892931, DOI: 10.1016/j.csm.2004.12.005.Peer-Reviewed Original Research
2004
Addition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response
Sanacora G, Berman RM, Cappiello A, Oren DA, Kugaya A, Liu N, Gueorguieva R, Fasula D, Charney DS. Addition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response. Neuropsychopharmacology 2004, 29: 1166-1171. PMID: 15010697, DOI: 10.1038/sj.npp.1300418.Peer-Reviewed Original ResearchConceptsHamilton depression scale ratingsΑ2-antagonist yohimbineAntidepressant responseClinical Global Impression ratingsBlood pressure changesPercentage of respondersLog-rank testGlobal Impression ratingsMajor depressive disorderMore rapid onsetP subjectsDSM-IV diagnosisSSRI agentsTitrated doseYohimbine doseAntidepressant actionAntidepressant medicationCGI scaleNoradrenergic toneMonoaminergic neurotransmissionΑ2-adrenoceptorsDepressive disorderTreatment periodOutcome measuresSCID interview
2003
Regional Brain Metabolic Correlates of α-Methylparatyrosine–Induced Depressive Symptoms: Implications for the Neural Circuitry of Depression
Bremner JD, Vythilingam M, Ng CK, Vermetten E, Nazeer A, Oren DA, Berman RM, Charney DS. Regional Brain Metabolic Correlates of α-Methylparatyrosine–Induced Depressive Symptoms: Implications for the Neural Circuitry of Depression. JAMA 2003, 289: 3125-3134. PMID: 12813118, PMCID: PMC3233764, DOI: 10.1001/jama.289.23.3125.Peer-Reviewed Original ResearchConceptsNorepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsBrain metabolic correlatesDepressive symptomsDorsolateral prefrontal cortexReuptake inhibitorsBrain metabolismMetabolic correlatesPrefrontal cortexPsychiatric research unitDouble-blind trialPositron emission tomography (PET) measurementsDepletion of norepinephrineSerotonin reuptake inhibitorsDifferent neurochemical systemsCommon brain circuitryAMPT administrationInitial medicationPlacebo administrationLimbic areasAcute decreaseDepressed patientsCortical areasPatientsDay 3
2002
Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression
Boutros NN, Gueorguieva R, Hoffman RE, Oren DA, Feingold A, Berman RM. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression. Psychiatry Research 2002, 113: 245-254. PMID: 12559481, DOI: 10.1016/s0165-1781(02)00267-6.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTreatment-resistant depressed patientsDepressed patientsTherapeutic effectActive repetitive transcranial magnetic stimulationStimulation parametersTreatment-resistant depressionDouble-blind designTranscranial magnetic stimulationLeft prefrontal cortexSham groupMagnetic stimulationStimulation courseRTMS stimulationPatientsSystematic followThreshold stimulationPrefrontal cortexFollowPre-set criteriaSignificant differencesStimulationWork daysWeeksConsecutive work daysMonoamine depletion in unmedicated depressed subjects
Berman RM, Sanacora G, Anand A, Roach LM, Fasula MK, Finkelstein CO, Wachen RM, Oren DA, Heninger GR, Charney DS. Monoamine depletion in unmedicated depressed subjects. Biological Psychiatry 2002, 51: 469-473. PMID: 11922881, DOI: 10.1016/s0006-3223(01)01285-9.Peer-Reviewed Original ResearchConceptsUnmedicated depressed subjectsDepressed subjectsCatecholamine depletionDepressed patientsMean Hamilton Depression Rating Scale scoreHamilton Depression Rating Scale scoresRandom-order crossover studyDepression Rating Scale scoresRating Scale scoresDepressed control subjectsSignificant mood changesMonoamine depletionCrossover studyCatecholamine functionControl subjectsMonoamine functionMonoamine systemsStudy daysClinical depressionScale scoreMood changesPatientsIndoleamineGreater increaseIndirect mechanisms
2001
Bright Light Therapy for Schizoaffective Disorder
OREN D, CUBELLS J, LITSCH S. Bright Light Therapy for Schizoaffective Disorder. American Journal Of Psychiatry 2001, 158: 2086-a-2087. PMID: 11729035, DOI: 10.1176/appi.ajp.158.12.2086-a.Peer-Reviewed Original Research
2000
No effect of light on basal glucagon levels in winter seasonal depressives and comparison subjects
Oren D, Berman R, Anand A, Charney D. No effect of light on basal glucagon levels in winter seasonal depressives and comparison subjects. Psychiatry Research 2000, 94: 263-266. PMID: 10889291, DOI: 10.1016/s0165-1781(00)00158-x.Peer-Reviewed Original ResearchAttenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists
Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH. Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists. JAMA Psychiatry 2000, 57: 270-276. PMID: 10711913, DOI: 10.1001/archpsyc.57.3.270.Peer-Reviewed Original ResearchMeSH KeywordsAdultAffectBrief Psychiatric Rating ScaleCognition DisordersDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleGlutamatesHumansKetamineLamotrigineMaleMental DisordersPerceptual DisordersPlacebosPsychiatric Status Rating ScalesReceptors, N-Methyl-D-AspartateSchizophreniaSchizophrenic PsychologyTriazinesVerbal LearningConceptsN-methyl-D-aspartate receptor antagonistNMDA receptor dysfunctionReceptor antagonistNeuropsychiatric effectsGlutamate releaseReceptor dysfunctionSymptom subscalesPlacebo 2 hoursClinician-Administered Dissociative States ScaleAdministration of lamotrigineAdministration of ketamineDouble-blind conditionsNMDA receptor antagonistMood-elevating effectsPositive symptom subscaleBrief Psychiatric RatingNovel therapeutic agentsNegative symptom subscaleHopkins Verbal Learning TestVerbal Learning TestKetamine effectsPsychiatric illnessHealthy subjectsPathophysiologic processesPreclinical studies